 | • レポートコード：QFJ1-4298 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、ヘモグロビン症用治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（鎮痛剤、抗生物質、ACE阻害剤、ヒドロキシウレア、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・ヘモグロビン症用治療薬の市場動向 ・企業の競争状況、市場シェア ・ヘモグロビン症用治療薬の種類別市場規模と予測2016-2027（鎮痛剤、抗生物質、ACE阻害剤、ヒドロキシウレア、その他） ・ヘモグロビン症用治療薬の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・ヘモグロビン症用治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・ヘモグロビン症用治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・ヘモグロビン症用治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ヘモグロビン症用治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・ヘモグロビン症用治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol-Myers Squibb Company、GlycoMimetics、Pfizer、Anthera Pharmaceuticals、Eli Lilly and Company、Mast Therapeutics、Daiichi Sankyo Company、Novartis、Bluebird Bio、HemaQuest Pharmaceuticals、Emmaus Medical、Prolong Pharmaceuticals、Merck、Medunik USA、Sangamo Therapeutics、Global Blood Therapeutics、Alnylam Pharmaceuticals、Acceleron Pharma） ・結論 |
Market Analysis and Insights: Global Hemoglobinopathy Treatment Drug Market
The global Hemoglobinopathy Treatment Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hemoglobinopathy Treatment Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hemoglobinopathy Treatment Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hemoglobinopathy Treatment Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hemoglobinopathy Treatment Drug market.
Global Hemoglobinopathy Treatment Drug Scope and Market Size
Hemoglobinopathy Treatment Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hemoglobinopathy Treatment Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb Company
GlycoMimetics
Pfizer
Anthera Pharmaceuticals
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company
Novartis
Bluebird Bio
HemaQuest Pharmaceuticals
Emmaus Medical
Prolong Pharmaceuticals
Merck
Medunik USA
Sangamo Therapeutics
Global Blood Therapeutics
Alnylam Pharmaceuticals
Acceleron Pharma
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemoglobinopathy Treatment Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Analgesics
1.2.3 Antibiotics
1.2.4 ACE Inhibitors
1.2.5 Hydroxyurea
1.2.6 Others
1.3 Market by Application
1.3.1 Global Hemoglobinopathy Treatment Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hemoglobinopathy Treatment Drug Market Perspective (2016-2027)
2.2 Hemoglobinopathy Treatment Drug Growth Trends by Regions
2.2.1 Hemoglobinopathy Treatment Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hemoglobinopathy Treatment Drug Historic Market Share by Regions (2016-2021)
2.2.3 Hemoglobinopathy Treatment Drug Forecasted Market Size by Regions (2022-2027)
2.3 Hemoglobinopathy Treatment Drug Industry Dynamic
2.3.1 Hemoglobinopathy Treatment Drug Market Trends
2.3.2 Hemoglobinopathy Treatment Drug Market Drivers
2.3.3 Hemoglobinopathy Treatment Drug Market Challenges
2.3.4 Hemoglobinopathy Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemoglobinopathy Treatment Drug Players by Revenue
3.1.1 Global Top Hemoglobinopathy Treatment Drug Players by Revenue (2016-2021)
3.1.2 Global Hemoglobinopathy Treatment Drug Revenue Market Share by Players (2016-2021)
3.2 Global Hemoglobinopathy Treatment Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hemoglobinopathy Treatment Drug Revenue
3.4 Global Hemoglobinopathy Treatment Drug Market Concentration Ratio
3.4.1 Global Hemoglobinopathy Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemoglobinopathy Treatment Drug Revenue in 2020
3.5 Hemoglobinopathy Treatment Drug Key Players Head office and Area Served
3.6 Key Players Hemoglobinopathy Treatment Drug Product Solution and Service
3.7 Date of Enter into Hemoglobinopathy Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemoglobinopathy Treatment Drug Breakdown Data by Type
4.1 Global Hemoglobinopathy Treatment Drug Historic Market Size by Type (2016-2021)
4.2 Global Hemoglobinopathy Treatment Drug Forecasted Market Size by Type (2022-2027)
5 Hemoglobinopathy Treatment Drug Breakdown Data by Application
5.1 Global Hemoglobinopathy Treatment Drug Historic Market Size by Application (2016-2021)
5.2 Global Hemoglobinopathy Treatment Drug Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Hemoglobinopathy Treatment Drug Market Size (2016-2027)
6.2 North America Hemoglobinopathy Treatment Drug Market Size by Type
6.2.1 North America Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021)
6.2.2 North America Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027)
6.2.3 North America Hemoglobinopathy Treatment Drug Market Size by Type (2016-2027)
6.3 North America Hemoglobinopathy Treatment Drug Market Size by Application
6.3.1 North America Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021)
6.3.2 North America Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027)
6.3.3 North America Hemoglobinopathy Treatment Drug Market Size by Application (2016-2027)
6.4 North America Hemoglobinopathy Treatment Drug Market Size by Country
6.4.1 North America Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021)
6.4.2 North America Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Hemoglobinopathy Treatment Drug Market Size (2016-2027)
7.2 Europe Hemoglobinopathy Treatment Drug Market Size by Type
7.2.1 Europe Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021)
7.2.2 Europe Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027)
7.2.3 Europe Hemoglobinopathy Treatment Drug Market Size by Type (2016-2027)
7.3 Europe Hemoglobinopathy Treatment Drug Market Size by Application
7.3.1 Europe Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021)
7.3.2 Europe Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027)
7.3.3 Europe Hemoglobinopathy Treatment Drug Market Size by Application (2016-2027)
7.4 Europe Hemoglobinopathy Treatment Drug Market Size by Country
7.4.1 Europe Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021)
7.4.2 Europe Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size (2016-2027)
8.2 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Type
8.2.1 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Application
8.3.1 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Region
8.4.1 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hemoglobinopathy Treatment Drug Market Size (2016-2027)
9.2 Latin America Hemoglobinopathy Treatment Drug Market Size by Type
9.2.1 Latin America Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021)
9.2.2 Latin America Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027)
9.2.3 Latin America Hemoglobinopathy Treatment Drug Market Size by Type (2016-2027)
9.3 Latin America Hemoglobinopathy Treatment Drug Market Size by Application
9.3.1 Latin America Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021)
9.3.2 Latin America Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027)
9.3.3 Latin America Hemoglobinopathy Treatment Drug Market Size by Application (2016-2027)
9.4 Latin America Hemoglobinopathy Treatment Drug Market Size by Country
9.4.1 Latin America Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021)
9.4.2 Latin America Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size (2016-2027)
10.2 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Type
10.2.1 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Application
10.3.1 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Country
10.4.1 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb Company
11.1.1 Bristol-Myers Squibb Company Company Details
11.1.2 Bristol-Myers Squibb Company Business Overview
11.1.3 Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Introduction
11.1.4 Bristol-Myers Squibb Company Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.1.5 Bristol-Myers Squibb Company Recent Development
11.2 GlycoMimetics
11.2.1 GlycoMimetics Company Details
11.2.2 GlycoMimetics Business Overview
11.2.3 GlycoMimetics Hemoglobinopathy Treatment Drug Introduction
11.2.4 GlycoMimetics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.2.5 GlycoMimetics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Hemoglobinopathy Treatment Drug Introduction
11.3.4 Pfizer Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Anthera Pharmaceuticals
11.4.1 Anthera Pharmaceuticals Company Details
11.4.2 Anthera Pharmaceuticals Business Overview
11.4.3 Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Introduction
11.4.4 Anthera Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.4.5 Anthera Pharmaceuticals Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Hemoglobinopathy Treatment Drug Introduction
11.5.4 Eli Lilly and Company Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.5.5 Eli Lilly and Company Recent Development
11.6 Mast Therapeutics
11.6.1 Mast Therapeutics Company Details
11.6.2 Mast Therapeutics Business Overview
11.6.3 Mast Therapeutics Hemoglobinopathy Treatment Drug Introduction
11.6.4 Mast Therapeutics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.6.5 Mast Therapeutics Recent Development
11.7 Daiichi Sankyo Company
11.7.1 Daiichi Sankyo Company Company Details
11.7.2 Daiichi Sankyo Company Business Overview
11.7.3 Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Introduction
11.7.4 Daiichi Sankyo Company Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.7.5 Daiichi Sankyo Company Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Hemoglobinopathy Treatment Drug Introduction
11.8.4 Novartis Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Bluebird Bio
11.9.1 Bluebird Bio Company Details
11.9.2 Bluebird Bio Business Overview
11.9.3 Bluebird Bio Hemoglobinopathy Treatment Drug Introduction
11.9.4 Bluebird Bio Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.9.5 Bluebird Bio Recent Development
11.10 HemaQuest Pharmaceuticals
11.10.1 HemaQuest Pharmaceuticals Company Details
11.10.2 HemaQuest Pharmaceuticals Business Overview
11.10.3 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Introduction
11.10.4 HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.10.5 HemaQuest Pharmaceuticals Recent Development
11.11 Emmaus Medical
11.11.1 Emmaus Medical Company Details
11.11.2 Emmaus Medical Business Overview
11.11.3 Emmaus Medical Hemoglobinopathy Treatment Drug Introduction
11.11.4 Emmaus Medical Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.11.5 Emmaus Medical Recent Development
11.12 Prolong Pharmaceuticals
11.12.1 Prolong Pharmaceuticals Company Details
11.12.2 Prolong Pharmaceuticals Business Overview
11.12.3 Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Introduction
11.12.4 Prolong Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.12.5 Prolong Pharmaceuticals Recent Development
11.13 Merck
11.13.1 Merck Company Details
11.13.2 Merck Business Overview
11.13.3 Merck Hemoglobinopathy Treatment Drug Introduction
11.13.4 Merck Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.13.5 Merck Recent Development
11.14 Medunik USA
11.14.1 Medunik USA Company Details
11.14.2 Medunik USA Business Overview
11.14.3 Medunik USA Hemoglobinopathy Treatment Drug Introduction
11.14.4 Medunik USA Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.14.5 Medunik USA Recent Development
11.15 Sangamo Therapeutics
11.15.1 Sangamo Therapeutics Company Details
11.15.2 Sangamo Therapeutics Business Overview
11.15.3 Sangamo Therapeutics Hemoglobinopathy Treatment Drug Introduction
11.15.4 Sangamo Therapeutics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.15.5 Sangamo Therapeutics Recent Development
11.16 Global Blood Therapeutics
11.16.1 Global Blood Therapeutics Company Details
11.16.2 Global Blood Therapeutics Business Overview
11.16.3 Global Blood Therapeutics Hemoglobinopathy Treatment Drug Introduction
11.16.4 Global Blood Therapeutics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.16.5 Global Blood Therapeutics Recent Development
11.17 Alnylam Pharmaceuticals
11.17.1 Alnylam Pharmaceuticals Company Details
11.17.2 Alnylam Pharmaceuticals Business Overview
11.17.3 Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Introduction
11.17.4 Alnylam Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.17.5 Alnylam Pharmaceuticals Recent Development
11.18 Acceleron Pharma
11.18.1 Acceleron Pharma Company Details
11.18.2 Acceleron Pharma Business Overview
11.18.3 Acceleron Pharma Hemoglobinopathy Treatment Drug Introduction
11.18.4 Acceleron Pharma Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021)
11.18.5 Acceleron Pharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Hemoglobinopathy Treatment Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Analgesics
Table 3. Key Players of Antibiotics
Table 4. Key Players of ACE Inhibitors
Table 5. Key Players of Hydroxyurea
Table 6. Key Players of Others
Table 7. Global Hemoglobinopathy Treatment Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Hemoglobinopathy Treatment Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Hemoglobinopathy Treatment Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Hemoglobinopathy Treatment Drug Market Share by Regions (2016-2021)
Table 11. Global Hemoglobinopathy Treatment Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Hemoglobinopathy Treatment Drug Market Share by Regions (2022-2027)
Table 13. Hemoglobinopathy Treatment Drug Market Trends
Table 14. Hemoglobinopathy Treatment Drug Market Drivers
Table 15. Hemoglobinopathy Treatment Drug Market Challenges
Table 16. Hemoglobinopathy Treatment Drug Market Restraints
Table 17. Global Hemoglobinopathy Treatment Drug Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Hemoglobinopathy Treatment Drug Market Share by Players (2016-2021)
Table 19. Global Top Hemoglobinopathy Treatment Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemoglobinopathy Treatment Drug as of 2020)
Table 20. Ranking of Global Top Hemoglobinopathy Treatment Drug Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Hemoglobinopathy Treatment Drug Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Hemoglobinopathy Treatment Drug Product Solution and Service
Table 24. Date of Enter into Hemoglobinopathy Treatment Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Hemoglobinopathy Treatment Drug Revenue Market Share by Type (2016-2021)
Table 28. Global Hemoglobinopathy Treatment Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Hemoglobinopathy Treatment Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Hemoglobinopathy Treatment Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Hemoglobinopathy Treatment Drug Revenue Market Share by Application (2016-2021)
Table 32. Global Hemoglobinopathy Treatment Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Hemoglobinopathy Treatment Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size by Country (2022-2027) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Company Details
Table 65. Bristol-Myers Squibb Company Business Overview
Table 66. Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Product
Table 67. Bristol-Myers Squibb Company Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 68. Bristol-Myers Squibb Company Recent Development
Table 69. GlycoMimetics Company Details
Table 70. GlycoMimetics Business Overview
Table 71. GlycoMimetics Hemoglobinopathy Treatment Drug Product
Table 72. GlycoMimetics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 73. GlycoMimetics Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Hemoglobinopathy Treatment Drug Product
Table 77. Pfizer Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Anthera Pharmaceuticals Company Details
Table 80. Anthera Pharmaceuticals Business Overview
Table 81. Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Product
Table 82. Anthera Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 83. Anthera Pharmaceuticals Recent Development
Table 84. Eli Lilly and Company Company Details
Table 85. Eli Lilly and Company Business Overview
Table 86. Eli Lilly and Company Hemoglobinopathy Treatment Drug Product
Table 87. Eli Lilly and Company Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 88. Eli Lilly and Company Recent Development
Table 89. Mast Therapeutics Company Details
Table 90. Mast Therapeutics Business Overview
Table 91. Mast Therapeutics Hemoglobinopathy Treatment Drug Product
Table 92. Mast Therapeutics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 93. Mast Therapeutics Recent Development
Table 94. Daiichi Sankyo Company Company Details
Table 95. Daiichi Sankyo Company Business Overview
Table 96. Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Product
Table 97. Daiichi Sankyo Company Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 98. Daiichi Sankyo Company Recent Development
Table 99. Novartis Company Details
Table 100. Novartis Business Overview
Table 101. Novartis Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 102. Novartis Recent Development
Table 103. Bluebird Bio Company Details
Table 104. Bluebird Bio Business Overview
Table 105. Bluebird Bio Hemoglobinopathy Treatment Drug Product
Table 106. Bluebird Bio Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 107. Bluebird Bio Recent Development
Table 108. HemaQuest Pharmaceuticals Company Details
Table 109. HemaQuest Pharmaceuticals Business Overview
Table 110. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Product
Table 111. HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 112. HemaQuest Pharmaceuticals Recent Development
Table 113. Emmaus Medical Company Details
Table 114. Emmaus Medical Business Overview
Table 115. Emmaus Medical Hemoglobinopathy Treatment Drug Product
Table 116. Emmaus Medical Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 117. Emmaus Medical Recent Development
Table 118. Prolong Pharmaceuticals Company Details
Table 119. Prolong Pharmaceuticals Business Overview
Table 120. Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Product
Table 121. Prolong Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 122. Prolong Pharmaceuticals Recent Development
Table 123. Merck Company Details
Table 124. Merck Business Overview
Table 125. Merck Hemoglobinopathy Treatment Drug Product
Table 126. Merck Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 127. Merck Recent Development
Table 128. Medunik USA Company Details
Table 129. Medunik USA Business Overview
Table 130. Medunik USA Hemoglobinopathy Treatment Drug Product
Table 131. Medunik USA Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 132. Medunik USA Recent Development
Table 133. Sangamo Therapeutics Company Details
Table 134. Sangamo Therapeutics Business Overview
Table 135. Sangamo Therapeutics Hemoglobinopathy Treatment Drug Product
Table 136. Sangamo Therapeutics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 137. Sangamo Therapeutics Recent Development
Table 138. Global Blood Therapeutics Company Details
Table 139. Global Blood Therapeutics Business Overview
Table 140. Global Blood Therapeutics Hemoglobinopathy Treatment Drug Product
Table 141. Global Blood Therapeutics Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 142. Global Blood Therapeutics Recent Development
Table 143. Alnylam Pharmaceuticals Company Details
Table 144. Alnylam Pharmaceuticals Business Overview
Table 145. Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Product
Table 146. Alnylam Pharmaceuticals Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 147. Alnylam Pharmaceuticals Recent Development
Table 148. Acceleron Pharma Company Details
Table 149. Acceleron Pharma Business Overview
Table 150. Acceleron Pharma Hemoglobinopathy Treatment Drug Product
Table 151. Acceleron Pharma Revenue in Hemoglobinopathy Treatment Drug Business (2016-2021) & (US$ Million)
Table 152. Acceleron Pharma Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemoglobinopathy Treatment Drug Market Share by Type: 2020 VS 2027
Figure 2. Analgesics Features
Figure 3. Antibiotics Features
Figure 4. ACE Inhibitors Features
Figure 5. Hydroxyurea Features
Figure 6. Others Features
Figure 7. Global Hemoglobinopathy Treatment Drug Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Online Pharmacy Case Studies
Figure 11. Hemoglobinopathy Treatment Drug Report Years Considered
Figure 12. Global Hemoglobinopathy Treatment Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Hemoglobinopathy Treatment Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Hemoglobinopathy Treatment Drug Market Share by Regions: 2020 VS 2027
Figure 15. Global Hemoglobinopathy Treatment Drug Market Share by Regions (2022-2027)
Figure 16. Global Hemoglobinopathy Treatment Drug Market Share by Players in 2020
Figure 17. Global Top Hemoglobinopathy Treatment Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemoglobinopathy Treatment Drug as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Hemoglobinopathy Treatment Drug Revenue in 2020
Figure 19. Global Hemoglobinopathy Treatment Drug Revenue Market Share by Type (2016-2021)
Figure 20. Global Hemoglobinopathy Treatment Drug Revenue Market Share by Type (2022-2027)
Figure 21. North America Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Hemoglobinopathy Treatment Drug Market Share by Type (2016-2027)
Figure 23. North America Hemoglobinopathy Treatment Drug Market Share by Application (2016-2027)
Figure 24. North America Hemoglobinopathy Treatment Drug Market Share by Country (2016-2027)
Figure 25. United States Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Hemoglobinopathy Treatment Drug Market Share by Type (2016-2027)
Figure 29. Europe Hemoglobinopathy Treatment Drug Market Share by Application (2016-2027)
Figure 30. Europe Hemoglobinopathy Treatment Drug Market Share by Country (2016-2027)
Figure 31. Germany Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Hemoglobinopathy Treatment Drug Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Hemoglobinopathy Treatment Drug Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Hemoglobinopathy Treatment Drug Market Share by Region (2016-2027)
Figure 41. China Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Hemoglobinopathy Treatment Drug Market Share by Type (2016-2027)
Figure 49. Latin America Hemoglobinopathy Treatment Drug Market Share by Application (2016-2027)
Figure 50. Latin America Hemoglobinopathy Treatment Drug Market Share by Country (2016-2027)
Figure 51. Mexico Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Hemoglobinopathy Treatment Drug Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Hemoglobinopathy Treatment Drug Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Hemoglobinopathy Treatment Drug Market Share by Country (2016-2027)
Figure 57. Turkey Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Hemoglobinopathy Treatment Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 61. GlycoMimetics Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 63. Anthera Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 64. Eli Lilly and Company Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 65. Mast Therapeutics Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 66. Daiichi Sankyo Company Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 68. Bluebird Bio Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 69. HemaQuest Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 70. Emmaus Medical Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 71. Prolong Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 72. Merck Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 73. Medunik USA Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 74. Sangamo Therapeutics Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 75. Global Blood Therapeutics Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 76. Alnylam Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 77. Acceleron Pharma Revenue Growth Rate in Hemoglobinopathy Treatment Drug Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
世界のヘモグロビン症治療市場規模・現状・予測（2021年-2027年） Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Market Analysis and Insights: Global Hemoglobinopathy Treatment Market The global Hemoglobinopathy Treatment market size is projected to reach US$ 384.7 million by 2027, from US$ 274.5 million in 202…- 世界のノイラミニダーゼ阻害薬市場規模・現状・予測（2021年-2027年） Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme. Market Analysis and Insights: Global Neuraminidase Inhibitors Drug Market The global Neuraminidase Inhibitors Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2…
- 世界のヘモグロビン症治療薬市場規模・現状・予測（2021年-2027年） Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Market Analysis and Insights: Global Hemoglobinopathy Drugs Market The global Hemoglobinopathy Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR o…
- 世界の小売薬局市場規模・現状・予測（2021年-2027年） A retail pharmacy refers to a retail store of medicines. Market Analysis and Insights: Global Retail Pharmacy Market The global Retail Pharmacy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in…
- 世界の風邪薬市場規模・現状・予測（2021年-2027年） This report focus on OTC drugs and wellness drugs to treat cold symptoms and respiratory infections. Market Analysis and Insights: Global Cold Treatment Drug Market The global Cold Treatment Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% …